نتایج جستجو برای: Infliximab

تعداد نتایج: 7105  

H Najafipour M.R SHakibi T GHadiri

Background & Aims: The anti TNF drugs are new line treatment for articular inflammatory diseases which are used systemically, but due to expensiveness and some systemic adverse effects have limited usage. The aims of this study were to investigate the effect of intra-articular (local) injection of Etanercept and Infliximab as two anti TNF drugs on histopathology and also due to the important ro...

Journal: :iranian journal of pharmaceutical sciences 0
najmeh moradi school of pharmacy, shahid beheshti university of medical sciences, tehran, iran shahram tofighi health management research center, baghiatallah university of medical sciences, tehran, iran marzieh zanganeh health insurance office, ministry of health and medical education, tehran, iran ali akbari sari school of public health, tehran university of medical sciences, tehran, iran hossein khedmat research center for gastroenterology and liver disease, baghiatallah university of medical sciences, tehran,iran leila zarei school of pharmacy, shahid beheshti university of medical sciences, tehran, iran

the aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe ulcerative colitis (uc) in iran. we developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. hypothetical patients, were individuals with moderate to sev...

The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients, were individuals with moderate to sev...

Journal: :galen medical journal 0
abbas zamanian associate professor of dermatology, rasoul-e-akram hospital, iran university of medical sciences, iran amir houshang ehsani assistant professor of dermatology, rasi hospital, tehran university of medical sciences, tehran, iran seyyedeh bahareh darvari resident of dermatology, rasoul-e-akram hospital, iran university of medical sciences, tehran, iran golnaz mehran assistant professor of dermatology, rasoul-e-akram hospital, iran university of medical sciences, iran arghavan azizpour resident of dermatology, razi hospital, tehran university of medical sciences, tehran, iran

background: psoriasis is a chronic and inflammatory dermatologic disease. inflammatory biomarkers such as c-reactive protein (crp) and erythrocyte sedimentation rate (esr) are known as immediate and delayed inflammatory biomarkers, respectively. due to the fact that anti-inflammatory drugs such as infliximab are widely used in psoriasis treatment, the aim of this study was to evaluate esr, crp ...

ژورنال: :کومش 0
جمیله مقیمی j moghimi dept. of internal medicine, fatemieh hospital, semnan university of medical sciences, semnan, iranدانشگاه علوم پزشکی سمنان، بیمارستان فاطمیه، گروه داخلی غلامرضا دارایی gh daraee dept. of ophthalmology, amiralmomenin hospital, semnan university of medical sciences, semnan, iranدانشگاه علوم پزشکی سمنان، بیمارستان امیرالمومنین (ع)، گروه چشم پزشکی

بیماری بهجت یک سندرم واسکولیتی با درگیری چند ارگان است که دارای تریاد کلینیکی آفت های دهان و زخم های تناسلی و درگیری چشمی می باشد. درگیری چشمی بیماری بهجت می تواند به سمت از دست رفتن سریع بینایی پیش برود. این گزارش در رابطه با معرفی یک مرد 40 ساله با درگیری چشمی دوطرفه و شدید (پان یوئیت مقاوم به درمان) می باشد که ما جهت کنترل آن infliximab را شروع کردیم و بعد از اولین تزریق وریدی پاسخ افتالمولو...

Journal: :bulletin of emergency and trauma 0
saman nikeghbalian homeira vafaei farid moradian kourosh kazemi nader tanideh leila shayan msc, trauma research center, shiraz university of medical sciences, shiraz, iran

objectives: to investigate the effects of intravenous infliximab in preventing the formation of peritoneal adhesions in an animal model of rat. methods: this was an experimental study being performed in animal laboratory of shiraz university of medical sciences during 2012. sixty albino rats were randomly assigned in to three groups by random design method. the first group received single infli...

Journal: :Scandinavian journal of gastroenterology 2011
Casper Steenholdt Klaus Bendtzen Jørn Brynskov Ole Østergaard Thomsen Mark Andrew Ainsworth

INTRODUCTION Reasons for infliximab failure in Crohn's disease and ulcerative colitis are debated. Serum levels of infliximab and anti-infliximab antibodies have been associated with loss of response. We aimed at determining cut-off levels for infliximab and anti-infliximab antibody concentrations associated with clinical response to infliximab maintenance therapy. METHODS Patients with infla...

تیموریان, شهرام, سرابی‌نژاد, زهره, نوری اینانلو, داود,

Background: Infeliximab is a form of chimeric antibody which neutralizes the most important inflammatory cytokine, TNF-a, in inflammatory disorders. The aim of current study was to pilot expression of chimeric infliximab in Chinese Hamster ovary (CHO) cells. Methods: In this research study, pVITRO2-neo-mcs vector that consist of infliximab light chain and heavy chain was used to transform in...

2011
Bart JF van den Bemt Alfons A den Broeder GJ Wolbink Yechiel A Hekster Piet LCM van Riel Bart Benraad Frank HJ van den Hoogen

BACKGROUND This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusion cycle to assess at what moment patients develop low/no infliximab trough levels and/or detectable anti-infliximab levels. METHODS Infliximab treated RA patients were included in this descriptive open-label cohort study. Durin...

Journal: :The British journal of ophthalmology 2011
Yukiko Yamada Sunao Sugita Hiroyuki Tanaka Koju Kamoi Hiroshi Takase Manabu Mochizuki

AIM To investigate the relationship between recurrence of uveitis and timing of infliximab in patients with Behçet's disease. METHODS Charts were retrospectively reviewed for 23 patients with refractory uveoretinitis associated with Behçet's disease treated using infliximab at our hospital. Infliximab was administered by intravenous infusion at weeks 0, 2 and 6, and every 8 weeks thereafter. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید